Patents by Inventor Miles Goodman Siegel

Miles Goodman Siegel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CGRP ANTIGONISTS USEFUL AS TRACER COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY
    Publication number: 20230096051
    Abstract: The present invention provides a compound of Formula I: wherein R1 is hydrogen, F, or 18F; and R2 is hydrogen, F, or 18F; or a pharmaceutically acceptable salt thereof, provided that when R1 is 18F then R2 is not 18F, useful as a CGRP receptor antagonist for PET imaging.
    Type: Application
    Filed: December 4, 2020
    Publication date: March 30, 2023
    Inventors: Mark Donald CHAPPELL, Miles Goodman SIEGEL
  • 3-methyl-pyrrolidine-2,5-dione derivatives useful as CGRP receptor antagonists
    Patent number: 10336726
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt or hydrate thereof, useful as a CGRP receptor antagonist.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: July 2, 2019
    Assignee: Eli Lilly and Company
    Inventors: Jennifer Anne McMahon, Miles Goodman Siegel, Russell Dean Stucky
  • 3-METHYL-PYRROLIDINE-2,5-DIONE DERIVATIVES USEFUL AS CGRP RECEPTOR ANTAGONISTS
    Publication number: 20180327384
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt or hydrate thereof, useful as a CGRP receptor antagonist.
    Type: Application
    Filed: May 8, 2018
    Publication date: November 15, 2018
    Inventors: Jennifer Anne McMahon, Miles Goodman Siegel, Russell Dean Stucky
  • CGRP receptor antagonists
    Patent number: 9708297
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: July 18, 2017
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Kevin Charles Fortner, Steven Marc Massey, Jason Kenneth Myers, Antonio Navarro, Miles Goodman Siegel, Russell Dean Stucky
  • CGRP receptor antagonists
    Patent number: 9637495
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: May 2, 2017
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Kevin Charles Fortner, Richard Duane Johnston, Steven Marc Massey, Jason Kenneth Myers, Qing Shi, Miles Goodman Siegel
  • CGRP RECEPTOR ANTAGONISTS
    Publication number: 20170044163
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 5, 2016
    Publication date: February 16, 2017
    Inventors: David Andrew Coates, Kevin Charles Fortner, Richard Duane Johnston, Steven Marc Massey, Jason Kenneth Myers, Qing Shi, Miles Goodman Siegel
  • CGRP RECEPTOR ANTAGONISTS
    Publication number: 20170044138
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 5, 2016
    Publication date: February 16, 2017
    Inventors: David Andrew Coates, Kevin Charles Fortner, Steven Marc Massey, Jason Kenneth Myers, Antonio Navarro, Miles Goodman Siegel, Russell Dean Stucky
  • 6-substituted nicotinamide derivatives as opioid receptor antagonists
    Patent number: 8101638
    Abstract: A compound of the formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate, diasteromers or mixtures thereof, or a solvate thereof, formulations and methods of use thereof, as opioid receptor antagonists are disclosed wherein the variables are as described herein.
    Type: Grant
    Filed: July 8, 2008
    Date of Patent: January 24, 2012
    Assignee: Eli Lilly and Company
    Inventors: Miles Goodman Siegel, Russell Dean Stucky, Kumiko Takeuchi
  • Opioid Receptor Antagonists
    Publication number: 20110105571
    Abstract: A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3?, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Application
    Filed: January 6, 2011
    Publication date: May 5, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Mark Donald Chappell, Charles Howard Mitch, Steven James Quimby, Miles Goodman Siegel
  • Opioid receptor antagonists
    Patent number: 7902372
    Abstract: A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3?, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Grant
    Filed: April 2, 2008
    Date of Patent: March 8, 2011
    Assignee: Eli Lilly and Company
    Inventors: Mark Donald Chappell, Charles Howard Mitch, Steven James Quimby, Miles Goodman Siegel
  • 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20090023785
    Abstract: A compound of the formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate, diasteromers or mixtures thereof, or a solvate thereof, formulations and methods of use thereof, as opioid receptor antagonists are disclosed wherein the variables are as described herein.
    Type: Application
    Filed: July 8, 2008
    Publication date: January 22, 2009
    Inventors: Concepcion Pedregal-Tercero, Miles Goodman Siegel, Russell Dean Stucky, Kumiko Takeuchi
  • DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20080269296
    Abstract: A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3?, E, v, y, z. A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Application
    Filed: March 21, 2008
    Publication date: October 30, 2008
    Inventors: Maria-Jesus Blanco-Pillado, Mark Donald Chappell, Marta Garcia De La Torre, Nuria Diaz Buezo, James Erwin Fritz, William Glen Holloway, James Edward Matt, Charles Howard Mitch, Concepcion Pedregal-Tercero, Steven James Quimby, Miles Goodman Siegel, Dana Rae Smith, Russell Dean Stucky, Kumiko Takeuchi, Elizabeth Marie Thomas, Chad Nolan Wolfe
  • DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20080255152
    Abstract: A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3?, E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Application
    Filed: March 21, 2008
    Publication date: October 16, 2008
    Inventors: Maria-Jesus Blanco-Pillado, Mark Donald Chappell, Marta Garcia De La Torre, Nuria Diaz Buezo, James Erwin Fritz, William Glen Holloway, James Edward Matt, Charies Howard Mitch, Concepcion Pedregal-Tercero, Steven James Quimby, Miles Goodman Siegel, Dana Rae Smith, Russell Dean Stucky, Kumiko Takeuchi, Elizabeth Marie Thomas, Chad Nolan Wolfe
  • OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20080207701
    Abstract: A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3?, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Application
    Filed: April 2, 2008
    Publication date: August 28, 2008
    Inventors: Mark Donald Chappell, Charles Howard Mitch, Steven James Quimby, Miles Goodman Siegel
  • 6-substituted nicotinamide derivatives as opioid receptor antagonists
    Patent number: 7399774
    Abstract: A compound of the formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate, diastereomers or mixtures thereof, or a solvate thereof, formulations and methods of use thereof, as opioid receptor antagonists are disclosed wherein the variables are as described herein.
    Type: Grant
    Filed: February 25, 2004
    Date of Patent: July 15, 2008
    Assignee: Eli Lilly and Company
    Inventors: Miles Goodman Siegel, Russell Dean Stucky, Kumiko Takeuchi
  • Diphenylether amide derivatives as opioid receptor antagonists
    Patent number: 7378448
    Abstract: A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3?, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed
    Type: Grant
    Filed: March 2, 2005
    Date of Patent: May 27, 2008
    Assignee: Eli Lilly and Company
    Inventors: Charles Howard Mitch, Steven James Quimby, Miles Goodman Siegel
  • Beta3 adrenergic agonists
    Publication number: 20040242633
    Abstract: The present invention relates to a &bgr;3 adrenergic receptor agonist of formula I: 1
    Type: Application
    Filed: May 4, 2004
    Publication date: December 2, 2004
    Inventors: Britta Evers, Cynthia Darshini Jesudason, Rushad Eruch Karanjawala, David Michael Remick, Gerd Ruehter, Daniel Jon Sall, Theo Schotten, Miles Goodman Siegel, Wolfgang Stenzel, Russell Dean Stucky, John Arnold Werner
  • &bgr;3 adrenergic agonists
    Patent number: 6730792
    Abstract: The present invention relates to a &bgr;3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof, which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type II diabetes and/or obesity. The compound can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compound can be used to reduced neurogenic inflammation or as an antidepressant agent. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: May 4, 2004
    Assignee: Eli Lilly and Company
    Inventors: Britta Evers, Cynthia Darshini Jesudason, Rushad Eruch Karanjawala, David Michael Remick, Daniel Jon Sall, Miles Goodman Siegel, Wolfgang Stenzel, Russell Dean Stucky, John Arnold Werner
  • Beta3 adrenergic agonists
    Publication number: 20030191156
    Abstract: The present invention relates to a &bgr;3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof, which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type II diabetes and/or obesity. The compound can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compound can be used to reduced neurogenic inflammation or as an antidepressant agent. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.
    Type: Application
    Filed: December 13, 2002
    Publication date: October 9, 2003
    Inventors: Britta Evers, Cynthia Darshini Jesudason, Rushad Eruch Karanjawala, David Michael Remick, Daniel Jon Sall, Miles Goodman Siegel, Wolfgang Stenzel, Russell Dean Stucky, John Arnold Werner